key: cord-1049788-btwlkjjz authors: Heck, Johannes; Stichtenoth, Dirk O.; Mettin, Roland; Jöckel, Jörg; Bickel, Christoph; Krichevsky, Benjamin title: Remdesivir-induced symmetrical drug–related intertriginous and flexural exanthema (SDRIFE)? A case report with review of the literature date: 2020-08-06 journal: Eur J Clin Pharmacol DOI: 10.1007/s00228-020-02955-4 sha: 27d640a4b82b33dd61ad47eab41c6e6d58b6105f doc_id: 1049788 cord_uid: btwlkjjz nan Remdesivir is an antiviral agent which is under clinical investigation for the treatment of coronavirus disease 2019 (COVID-19) [1] . Besides hypotension, deep-vein thrombosis, and delirium, rash has been reported as adverse drug reaction (ADR) of remdesivir [2] . The term "rash", although commonly applied in clinical trials, is too unspecific to allow for a differentiated cutaneous ADR (cADR) management. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is an immune-mediated cADR which occurs after systemic administration of a drug in an individual without prior sensitization [3, 4] . SDRIFE is clinically defined by five criteria: (i) onset after initial or repeated exposure to a systemically administered drug (contact allergens excluded), (ii) sharply demarcated erythema in the gluteal/perianal area and/or V-shaped erythema in the inguinal/perigenital region, (iii) involvement of at least one other intertriginous/flexural fold (e.g., axillae, antecubital fossae), (iv) symmetrical distribution, and (v) absence of systemic involvement [4] . Beta-lactam antibiotics, especially amoxicillin, are recognized as the most frequent trigger of SDRIFE [4, 5] . The clinical course of SDRIFE usually is benign and self-limited. SDRIFE may, however, progress to a generalized maculopapular exanthema if the eliciting drug is not withdrawn [6] . Treatment of SDRIFE consists of discontinuation of the offending agent. Additionally, antihistamines and topical/ systemic glucocorticosteroids may provide symptomatic relief and speed up the healing process [5, 7, 8] . A 67-year-old male patient suffering from COVID-19 was transferred from Northern Italy to the Central Hospital of the German Armed Forces (Bundeswehrzentralkrankenhaus) Koblenz, Germany, on March 29, 2020, as part of an international medical evacuation operation. The patient had been mechanically ventilated since March 19 due to acute respiratory distress syndrome (ARDS). In Italy, the patient had been treated with intravenous remdesivir on a compassionate-use basis for four consecutive days (March 26 to 29). On March 30, the patient developed an erythematous macular exanthema on his trunk with pronounced involvement of both axillae, the inguinal and submental region. Remarkably, serous bullae with a diameter of up to 6 cm emerged in his axillae. The patient was physically examined by a senior dermatologist who established the diagnosis SDRIFE. Besides remdesivir, the patient was or had been treated with sufentanil, propofol, norepinephrine, pantoprazole, macrogol, metoclopramide, and enoxaparin. To evaluate the likelihood of each drug with regard to SDRIFE, we applied the Naranjo ADR Probability Scale (scale ranging from − 4 to + 13, with higher scores indicating a higher probability) [9] . The score for remdesivir was + 3 and for sufentanil, propofol, norepinephrine, pantoprazole, macrogol, metoclopramide, and enoxaparin was + 1, respectively, suggesting remdesivir as the primary offending agent. For a comprehensive medication chart of our patient as well as a detailed calculation of the score of each administered drug on the Naranjo ADR Probability Scale, please refer to Supplementary Table 1. Because of the concomitant viral ARDS, we refrained from glucocorticosteroid application. SDRIFE resolved spontaneously over the following weeks without further intervention. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00228-020-02955-4) contains supplementary material, which is available to authorized users. PubMed was searched for case reports/series of SDRIFE in order to update preexisting lists of SDRIFE-eliciting drugs [3-5, 10, 11] . All identified publications were reviewed, and SDRIFEeliciting drugs were extracted. We provide a comprehensive summary of currently known triggers of SDRIFE (Table 1) . Depending on the clinical context, the differential diagnosis of SDRIFE includes other cADRs such as acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, and (multifocal) fixed drug eruption, as well as nondrug-related dermatologic conditions, e.g., tinea cruris and inverse psoriasis [5, 7, 11] . A plethora of cutaneous manifestations have been described in connection with COVID-19 [47] , including an SDRIFE-like exanthema [48] . However, the clear temporal relationship between the start of treatment with remdesivir and the development of the exanthema as well as the improvement of the exanthema upon cessation of remdesivir lead us to the conclusion that our patient experienced an SDRIFE elicited by remdesivir. Nevertheless, we cannot rule out that the comedication contributed to the development of SDRIFE in the presented case. Conflict of interest The authors declare that they have no conflict of interest. Consent for publication Informed consent for publication was obtained from the patient's legal guardian. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Remdesivir for the treatment of Covid-19 -preliminary report Compassionate use of remdesivir for patients with severe Covid-19 A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE): a closer look at these conditions and an approach to intertriginous eruptions Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Symmetrical drug related intertriginous and flexural exanthema (SDRIFE) induced by fluconazole: an uncommon side effect of a commonly used drug Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by mefenamic acid Symmetrical drug-related intertriginous and flexural exanthema induced by doxycycline Symmetrical drug-related intertriginous and flexural exanthema induced by clarithromycin A method for estimating the probability of adverse drug reactions Pustulobullous variant of SDRIFE (symmetrical drug-related intertriginous and flexural exanthema) Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) associated with pristinamycin, secnidazole, and nefopam, with a review of the literature Symmetrical drug-related intertriginous and flexural exanthema caused by celecoxib Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) caused by etoricoxib SDRIFE (baboon syndrome) due to paracetamol: case report Symmetrical drug-related intertriginous and flexural exanthema due to codeine An unusual case of worsening cellulitis: baboon syndrome or SDRIFE Symmetrical drug-related intertriginous and flexural exanthema (baboon syndrome) induced by amoxicillin-clavulanate Odyakmaz Demirsoy E (2014) Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by oral metronidazole Symmetrical drug-related intertriginous and flexural exanthema due to clindamycin Symmetric, drug-related, intertriginous, and flexural exanthema in a patient with polyvalent intolerance to corticosteroids Symmetrical drug-related intertriginous and flexural exanthema induced by two different antibiotics Baboon syndrome: an unusual complication arising from antibiotic treatment of tonsillitis and review of the literature Symmetric drugrelated Intertriginous and flexural exanthema due to itraconazole: an uncommon side effect of a commonly used drug Symmetrical drug-related intertriginous and flexural exanthema secondary to topical 5-fluorouracil Symmetrical drug-related intertriginous and flexural exanthema caused by valacyclovir Symmetrical drug-related intertriginous and flexural exanthema (baboon syndrome) induced by omeprazole Symmetrical drug-related intertriginous and flexural exanthema due to ranitidine Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with infliximab Systemic drug-related intertriginous and flexural exanthema (SDRIFE) Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by golimumab Systemic contact dermatitis due to deflazacort Baboon syndrome due to a polysensitization with corticosteroids Everolimus-induced symmetrical drug-related Symmetrical Intertriginous and flexural exanthema due to bortezomib (a proteasome inhibitor) given for myeloma Symmetrical drug-related intertriginous and flexural exanthema secondary to epidermal growth factor receptor inhibitor gefitinib A rare case of clozapine-induced symmetrical drug-related intertriginous and flexural exanthema with vasculitis-like lesions First case of symmetric drug-related intertriginous and flexural exanthema (sdrife) due to rivastigmine? Baboon syndrome induced by hydroxyzine Vareniclineinduced symmetrical drug-related intertriginous and flexural exanthema Recurrent flexural exanthema (SDRIFE or baboon syndrome) after administration of two different iodinated radio contrast media A case of SDRIFE induced by Nuvaring® Zoledronic acid-associated symmetrical drugrelated intertriginous and flexural exanthema (SDRIFE): report of baboon syndrome in a woman with recurrent metastatic breast cancer after receiving zoledronic acid First case of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) due to Berberine, an over-the-counter herbal glycemic control agent Tacrolimus-induced symmetric drug-related intertriginous and flexural exanthema (SDRIFE) Symmetrical drug-related intertriginous and flexural exanthema possibly due to thiamine disulfide A rare case of musk anti-hemorrhoids ointment-induced symmetrical drug-related intertriginous and flexural exanthema Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases A distinctive skin rash associated with coronavirus disease 2019? Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations